Abstract
Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.
Original language | English (US) |
---|---|
Pages (from-to) | 871-880 |
Number of pages | 10 |
Journal | Nuclear Medicine Communications |
Volume | 39 |
Issue number | 10 |
DOIs | |
State | Published - Oct 1 2018 |
Keywords
- 68 Ga-PET/MRI
- 68 Ga-PSMA PET/CT
- high-risk prostate cancer
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging